2024 World Conference on Lung Cancer (WCLC) - Posters-P3.06E.06 Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

P3.06E.06 Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Back to course

Pdf Summary

The study investigates the prognostic and predictive value of angiogenesis and immune-related biomarkers in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Specifically, it examines baseline and post-treatment serum levels of VEGF-A, VEGF-B, soluble programmed cell death-1 (sPD-1), and soluble programmed cell death-ligand 1 (sPD-L1). <br /><br />The study included 55 patients, with 65.5% undergoing chemotherapy and pembrolizumab combination therapy, while others received pembrolizumab monotherapy. The mean patient age was 66.5 years. The results showed a significant decrease in VEGF-B levels and an increase in sPD-1 levels after treatment. VEGF-A and sPD-L1 levels also exhibited changes, but these were not statistically significant.<br /><br />Univariate Cox regression analysis revealed that higher pre-treatment levels of sPD-1 and sPD-L1, as well as higher post-treatment levels of VEGF-B, were significantly associated with reduced overall survival (OS). Multivariate analysis confirmed that elevated post-treatment VEGF-B and pre-treatment sPD-L1 levels hold prognostic significance, indicating they could serve as independent biomarkers for predicting outcomes in NSCLC patients treated with ICIs.<br /><br />The study underscores the potential role of sPD-L1 and VEGF-B as biomarkers in the management of advanced NSCLC. These findings provide valuable insights into the complex interactions between angiogenesis and immune factors within the tumor microenvironment, which could inform more personalized treatment strategies for NSCLC patients.<br /><br />In summary, the research suggests that monitoring sPD-L1 and VEGF-B could aid in predicting prognosis and treatment response, thereby enhancing the effectiveness of immunotherapy regimens in NSCLC.

Asset Subtitle

Konstantinos Syrigos

Meta Tag

Speaker Konstantinos Syrigos

Topic Pathology & Biomarkers

Keywords

angiogenesis

immune biomarkers

NSCLC

immune checkpoint inhibitors

VEGF-B

sPD-1

sPD-L1

prognostic significance

personalized treatment

immunotherapy